Dr. Michael Ong

  • Abstract 5000: A phase 3 trial with a 2×2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novometastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
  • Abstract 5002: Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.